Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are indicated in type 2 diabetes and obesity for their high efficacy in controlling glycaemia and inducing body weight loss, respectively. Patients may develop gastrointestinal adverse events (GI AEs), namely nausea, vomiting, diarrhoea and/or co...

Descripción completa

Detalles Bibliográficos
Autores principales: Gorgojo-Martínez, Juan J., Mezquita-Raya, Pedro, Carretero-Gómez, Juana, Castro, Almudena, Cebrián-Cuenca, Ana, de Torres-Sánchez, Alejandra, García-de-Lucas, María Dolores, Núñez, Julio, Obaya, Juan Carlos, Soler, María José, Górriz, José Luis, Rubio-Herrera, Miguel Ángel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821052/
https://www.ncbi.nlm.nih.gov/pubmed/36614945
http://dx.doi.org/10.3390/jcm12010145

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821052/
https://www.ncbi.nlm.nih.gov/pubmed/36614945
http://dx.doi.org/10.3390/jcm12010145

Ejemplares similares